多发性骨髓瘤患者血清β_2微球蛋白和高敏C反应蛋白检测的临床意义  

Measurement of Serum Levels ofβ2-microglobulin and high-sensitivity C-reactive protein in Multiple Myeloma and their Clinical Significances

作　　者：邓正辉[1] 李龙平[1] 王新华[1] 周忠[1] 

机构地区：[1]中南大学湘雅医学院益阳临床学院,湖南益阳413000

出　　处：《中国医疗前沿》2008年第6期94-95,共2页China Healthcare Innovation

摘　　要：目的探讨多发性骨髓瘤(MM)患者血清β2微球蛋白(β2-MG)和高敏C反应蛋白(hsCRP)的变化及其临床意义。方法采用胶乳增强免疫透射比浊法检测对150例MM患者(MM组)和50例正常体检者(对照组)的血清β2-MG和hsCRP水平,对比分析不同临床分期及治疗前后的血清β2-MG和hsCRP的变化。结果MM组血清β2-MG和hsCRP水平明显高于对照组,且随临床分期的增加依次增高,差异有统计学意义,均P<0.01。与治疗前相比,MM治疗有效组血清β2-MG和hsCRP水平明显下降,差异有统计学意义,均P<0.01(t=8.448,18.390),而治疗无效组则差异无统计学意义,均P>0.05(t=1.525,1.495)。结论血清β2-MG和hsCRP检测可用于MM患者的临床分期、疗效监测和预后判断。Objective To investigate the changes of the serum levels of β2-microglobulin(β2-MG)and high-sensitivity C-reactive protein(hsCRP) in patients with multiple myeloma(MM) and their clinical implications.Methods TThe latex-enhanced immunity transmission turbidity method was employed to measure the serum β2-MG and hsCRP levels between 150 MM patients(MM group) and 50 healthy controls(control group),and a comparative analysis was performed concerning the alterations in serum varyingβ2-MG and hsCRP levels of the v...

关 键 词：多发性骨髓瘤 Β2微球蛋白 C-反应蛋白 

分 类 号：R733.3[医药卫生—肿瘤]